This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Trudeau, V. Articles by Ebersole, J. Search for Related Content PubMed PubMed Citation Articles by Trudeau, V. Articles by Ebersole, J. Social Bookmarking                   What's this?

Gabapentin in Naive Childhood Absence Epilepsy: Results From Two Double-Blind, Placebo-Controlled, Multicenter Studies

Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Morris Plains, NJ

Sharie Myers, MA

Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Morris Plains, NJ

Linda LaMoreaux, MPH

Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Morris Plains, NJ

Henning Anhut, PhD

Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Freiburg, Germany

Elizabeth Garofalo, MD

Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Morris Plains, NJ

John Ebersole, MD

VA Medical Center West Haven, CT

Efficacy and safety of gabapentin monotherapy were evaluated in 33 children with newly diagnosed absence epilepsy in two identical, double-blind, placebo-controlled trials in which a 2-week double-blind treatment phase was followed by a 6-week open-label phase. Primary efficacy criterion was seizure frequency change from baseline to end of double-blind treatment derived from quantified electroencephalograms. Primary efficacy analyses compared treatment differences in the 2-week double-blind phase. Gabapentin did not significantly decrease or increase seizure frequency compared with placebo. Low dosages with possibly subtherapeutic plasma levels may have contributed to the lack of demonstrable efficacy. Somnolence and dizziness were the only adverse events reported by at least two patients during gabapentin treatment. No clinically important changes in laboratory assessments or other safety parameters were observed. Gabapentin monotherapy at dosages ranging from 9.7 through 19.1 mg/kg/day is well tolerated in pediatric patients aged 4 through 12 years with absence epilepsy. (J Child Neurol 1996;11:470-475).

Journal of Child Neurology, Vol. 11, No. 6, 470-475 (1996)
DOI: 10.1177/088307389601100611


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. A. French, A. M. Kanner, J. Bautista, B. Abou-Khalil, T. Browne, C. L. Harden, W. H. Theodore, C. Bazil, J. Stern, S. C. Schachter, et al. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society Neurology, April 27, 2004; 62(8): 1252 - 1260. [Abstract] [Full Text] [PDF]

				P. Kwan and M. J. Brodie Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy Neurology, June 10, 2003; 60(90114): S2 - 12. [Abstract] [Full Text]

				P. Camfield and C. Camfield Childhood Epilepsy: What Is the Evidence for What We Think and What We Do? J Child Neurol, April 1, 2003; 18(4): 272 - 287. [Abstract] [PDF]

				R. G. Jarrar and J. R. Buchhalter Therapeutics in Pediatric Epilepsy, Part 1: The New Antiepileptic Drugs and the Ketogenic Diet Mayo Clin. Proc., March 1, 2003; 78(3): 359 - 370. [Abstract] [PDF]

				J. W. Wheless Use of Topiramate in Childhood Generalized Seizure Disorders J Child Neurol, December 1, 2000; 15(1_suppl): S7 - S13. [Abstract] [PDF]

				J. M. Pellock Managing Pediatric Epilepsy Syndromes With New Antiepileptic Drugs Pediatrics, November 1, 1999; 104(5): 1106 - 1116. [Abstract] [Full Text]